highperformr logo

Caribou Biosciences's Overview

Total employees172
HeadquartersBerkeley
Founded2012

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by leveraging its proprietary Cas12a chRDNA (CRISPR hybrid RNA-DNA) genome-editing technology. The company is advancing a pipeline of wholly-owned, genome-edited, allogeneic CAR-T and CAR-NK cell therapies for the treatment of hematologic malignancies and solid tumors. Caribou's approach aims to develop 'off-the-shelf' cell therapies with enhanced anti-tumor activity and improved persistence.

Where is Caribou Biosciences's Headquarters?

HQ Function

The headquarters serves as the primary center for Caribou's research and development, clinical operations, manufacturing process development, and corporate functions.

Notable Features:

Located in the vibrant San Francisco Bay Area biotech hub, the facility houses state-of-the-art laboratories for CRISPR gene editing, cell line engineering, process development, and analytical characterization of cell therapies.

Work Culture:

Caribou fosters a collaborative, innovative, and science-driven work environment. The culture emphasizes scientific excellence, teamwork, and a shared commitment to developing novel therapies for patients with unmet medical needs.

HQ Significance:

The Berkeley headquarters is central to Caribou's operations, enabling the discovery, development, and advancement of its pipeline of next-generation allogeneic cell therapies.

Values Reflected in HQ: The headquarters' design and operational focus reflect Caribou's core values of scientific rigor, innovation, urgency in addressing patient needs, and collaboration in pursuit of transformative medicines.

Location:

While Caribou Biosciences is headquartered and primarily operates from its Berkeley, California facility, its focus on developing therapies for globally prevalent diseases like cancer means its research, clinical trials, and potential future commercialization efforts have international implications. The company may engage in collaborations or partnerships that extend its reach and impact worldwide, and its clinical trials often involve sites in multiple regions to ensure diverse patient participation.

Street Address:

2929 7th Street, Suite 105

City:

Berkeley

State/Province:

CA

Country:

USA

Caribou Biosciences's Global Presence

Buying Intent Signals for Caribou Biosciences

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Caribou Biosciences

As of April 2025, Caribou Biosciences' leadership includes:

Rachel Haurwitz, Ph.D. - President and Chief Executive Officer
Jason O’Byrne - Chief Financial Officer
Syed Rizvi, M.D. - Chief Medical Officer
Barbara G. McClung, J.D. - Chief Legal Officer and Corporate Secretary
Reuven Tsvi - Chief Business Officer
Chris L. Roberts - Chief Operating Officer
Christine G. O’Sullivan - Chief People Officer
Tim Kelly - Chief Technology Officer

Investors of Caribou Biosciences

Caribou Biosciences has been backed by several prominent investors over the years, including:

F-Prime Capital
GV (Google Ventures)
AbbVie Ventures
The Regents of the University of California
Pivotal bioVenture Partners
Pontifax AgTech
Ridgeback Capital Investments
PFM Health Sciences

Executive New Hires/Exits in the Last 12 Months

Hire2
Exits0

In the past 12 months, Caribou Biosciences has strengthened its executive team with key appointments, notably a new Chief Business Officer and a new Chief Operating Officer, to support its expanding clinical programs and operational capabilities. No high-profile executive departures were publicly announced during this period.

New Appointments:

Reuven Tsvi, Reuven Tsvi appointed as Chief Business Officer to lead business development and corporate strategy.
Chris L. Roberts, Chris L. Roberts appointed as Chief Operating Officer to oversee operations and manufacturing.

Technology (Tech Stack) used by Caribou Biosciences

Discover the tools Caribou Biosciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Caribou Biosciences Email Formats and Examples

Caribou Biosciences commonly uses the [first].[last]@cariboubio.com email format for its employees. While this is the most prevalent structure, other variations like [first_initial][last]@cariboubio.com might occasionally be used.

[first].[last]@cariboubio.com

Format

jane.doe@cariboubio.com

Example

75%

Success rate

News and media

Caribou Biosciences / GlobeNewswireMay 9, 2024

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

Caribou reported a net loss of $33.7 million for Q1 2024 and ended the quarter with $306.9 million in cash, cash equivalents, and marketable securities. The company highlighted progress in its CB-010 ANTLER trial, plans for initial data from its CB-011 CaMMouflage trial in H2 2024, and recent IND clearance for CB-012 in r/r AML....more

Caribou Biosciences / GlobeNewswireApril 2, 2024

Caribou Biosciences to Present Preclinical Data on CB-012, its Next-Generation Allogeneic CAR-T Cell Therapy, at the AACR Annual Meeting 2024

Caribou announced its presentation of preclinical data for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (r/r AML). The data showcased CB-012's enhanced anti-tumor activity due to its immune-cloaking strategy with a B2M knockout and B2M–HLA-E transgene insertion....more

Caribou Biosciences / GlobeNewswireFebruary 28, 2024

Caribou Biosciences Receives FDA Clearance of Investigational New Drug (IND) Application for CB-012, an Allogeneic CAR-T Cell Therapy with Checkpoint Disruption, for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Caribou announced that the U.S. Food and Drug Administration (FDA) cleared its IND application for CB-012, its lead allogeneic CAR-T cell therapy candidate from its Cas12a chRDNA-edited CAR-T cell platform for treating r/r AML. A Phase 1 clinical trial is planned for mid-2024....more

Caribou Biosciences / GlobeNewswireDecember 11, 2023

Caribou Biosciences Presents Promising Updated Clinical Data from CB-010 ANTLER Phase 1 Trial in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma at ASH Annual Meeting

Caribou presented updated results from its ANTLER Phase 1 trial for CB-010 in r/r B-NHL at the 65th ASH Annual Meeting. The data showed a 100% overall response rate and a 79% complete response rate (CR) at the initial dose level among 14 evaluable patients, with a 43% CR rate at 6 months....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Caribou Biosciences, are just a search away.